Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 0.959 USD -0.1% Market Closed
Market Cap: 23.3m USD

Enlivex Therapeutics Ltd
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Enlivex Therapeutics Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Operating Income
-$14.6m
CAGR 3-Years
17%
CAGR 5-Years
-10%
CAGR 10-Years
-1%
Kamada Ltd
NASDAQ:KMDA
Operating Income
$27.8m
CAGR 3-Years
N/A
CAGR 5-Years
5%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Operating Income
-$133.4m
CAGR 3-Years
-19%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Operating Income
-$10.8m
CAGR 3-Years
8%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Operating Income
-$23.3m
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
1%
M
Matricelf Ltd
TASE:MTLF
Operating Income
-₪16.1m
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
23.3m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
0.749 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Enlivex Therapeutics Ltd's Operating Income?
Operating Income
-14.6m USD

Based on the financial report for Sep 30, 2025, Enlivex Therapeutics Ltd's Operating Income amounts to -14.6m USD.

What is Enlivex Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 10Y
-1%

Over the last year, the Operating Income growth was 9%. The average annual Operating Income growth rates for Enlivex Therapeutics Ltd have been 17% over the past three years , -10% over the past five years , and -1% over the past ten years .

Back to Top